Printer Friendly

ALPHA 1 BIOMEDICALS COMPLETES ACQUISITION OF U.S. RIGHTS TO THYMOSIN ALPHA 1 FROM HOFFMANN-LA ROCHE

 ALPHA 1 BIOMEDICALS COMPLETES ACQUISITION OF U.S. RIGHTS TO
 THYMOSIN ALPHA 1 FROM HOFFMANN-LA ROCHE
 WASHINGTON, Dec. 23 /PRNewswire/ -- Alpha 1 Biomedicals, Inc. (NASDAQ: ALBM), today announced it has completed the acquisition of all U.S. rights to Thymosin alpha 1 from Hoffmann-La Roche, Inc., of Nutley, N.J. In September 1990, Alpha 1 Biomedicals purchased exclusive rights to Thymosin alpha 1 for treatment of chronic hepatitis B, lung cancer, and as an adjuvant for vaccines. In March of 1991, Alpha 1 Biomedicals acquired exclusive rights to Thymosin alpha 1 patents in 21 countries from Hoffmann-La Roche, Basle, Switzerland.
 Vincent F. Simmon, president and chief executive officer of Alpha 1 Biomedicals, stated: "This is the culmination of a process that began in 1982 when Dr. Allan Goldstein founded the company. Until this final agreement was reached, Roche had the right to reclaim Thymosin alpha 1, at their discretion, for a number of important therapies, including the treatment of chronic hepatitis C. Now, Alpha 1 Biomedicals is free to pursue the development of Thymosin alpha 1 for all potential indications."
 Thymosin alpha 1 is currently being evaluated in a multi-center Phase III clinical trial in the United States for the treatment of chronic hepatitis B, and is in a single center Phase III clinical trial in combination with alpha interferon for the treatment of chronic hepatitis C.
 Alpha 1 Biomedicals, Inc., is a Washington, D.C.-based company engaged in the development of peptide pharmaceutical products.
 -0- 12/23/91
 /CONTACT: Vincent F. Simmon of Alpha 1 Biomedicals, 202-628-9898; or Anita Monteith-Dixon of Long Ridge Associates, 203-790-0647, for Alpha 1 Biomedicals/
 (ALBM) CO: Alpha 1 Biomedicals, Inc.; Hoffmann-La Roche, Inc. ST: District of Columbia, New Jersey IN: MTC SU: TNM


GK-OS -- NY011 -- 4725 12/23/91 09:20 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 23, 1991
Words:299
Previous Article:YAMANOUCHI TO PURCHASE EQUITY POSITION IN ROBERTS PHARMACEUTICALS
Next Article:CYTOGEN INITIATES CLINICAL TRIALS FOR IMAGING NON-SMALL CELL LUNG CANCER
Topics:


Related Articles
ALPHA 1 BIOMEDICALS RECEIVES THE FIRST COMMERCIAL ORDER FOR THYMOSIN ALPHA 1
FIRST REGULATORY APPROVAL FOR THYMOSIN ALPHA 1
NEW AIDS DRUG STUDY ANNOUNCED; STANFORD RESEARCHERS TO STUDY THYMOSIN alpha I
THYMOSIN ALPHA 1 TO BE EVALUATED IN CLINICAL TRIAL IN MEXICO
ALPHA 1 BIOMEDICALS ANNOUNCES INITIATION OF ARBITRATION PROCEEDINGS WITH LICENSEE
ALPHA 1 BIOMEDICALS ANNOUNCES MANUFACTURING AGREEMENT FOR THYMOSIN ALPHA 1
ALPHA 1 BIOMEDICALS, INC., ANNOUNCES LAWSUIT BY SCICLONE PHARMACEUTICALS, INC.
ALPHA 1'S SUPPLIER EXPERIENCES MANUFACTURING DIFFICULTIES
ALPHA 1 BIOMEDICALS ENTERS INTO AN AGREEMENT TO SELL ITS 50% INTEREST IN AIDS TECHNOLOGY
ALPHA 1 BIOMEDICALS SIGNS DEFINITIVE MERGER AGREEMENT

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters